Physician profile
Donald Mario Sesso
NPI 1558437566
$22,929.27
in general payments reported to CMS, 2019-2025
27 companies · $8,689 in 2025
The $8,689 reported for 2025 was more than what 97% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $1,278 · 2021: $443 · 2022: $386 · 2023: $1,810 · 2024: $9,656 · 2025: $8,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $1,613 · Travel and Lodging: $41.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,500.00 |
| Food and Beverage | $1,612.50 |
| Travel and Lodging | $41.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $19,394.89 | 2022-2025 | |
| Aerin Medical INC. | $1,324.65 | 2019-2020 | |
| Intersect Ent, INC. | $313.08 | 2019-2022 | |
| Acclarent, INC | $210.97 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $135.80 | 2021 | |
| Medtronic, INC. | $135.64 | 2024-2025 | Propel, Sinuva |
| Astrazeneca Pharmaceuticals Lp | $121.07 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $115.00 | 2024 | Orladeyo |
| Phathom Pharmaceuticals, INC. | $115.00 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $115.00 | 2023 | Acthar |
| Valeritas, INC. | $114.31 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $112.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $112.71 | 2022 | |
| Glaxosmithkline, LLC. | $106.72 | 2024-2025 | Nucala |
| Insmed, INC. | $106.47 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $103.74 | 2019 | |
| Stryker Corporation | $55.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.50 | 2025 | Dupixent |
| Neurent Medical Limited | $40.04 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Integra Lifesciences Corporation | $23.21 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Merck Sharp & Dohme LLC | $22.19 | 2023 | |
| Bard Access Systems, INC. | $20.75 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.29 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $18.22 | 2024 | Ryaltris |
| Kowa Pharmaceuticals America, INC. | $16.25 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $14.92 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Sesso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.